The booming trade in legal highs will go underground in the face of blanket bans, such as that now being debated in Britain, European drug experts have warned in the annual report of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). They say online "grey marketplaces" selling new psychoactive substances (NPS) and greater use of social media are emerging as alternatives to the high street "head shops" and public websites likely to be shut down by laws enforcing a blanket ban on the trade. (See also: Legal highs: which drugs will be banned in the UK?)
Minister of Industry, Investment and Commerce, Anthony Hylton, says Jamaica intends to lead a charge in the United Nations to effect changes to the international treaties concerning marijuana. The aim is to change the schedule class of marijuana in light of scientific studies that have proven its therapeutic benefits and medicinal value. "Jamaica intends to participate, and to lead, if necessary, a process in the United Nations to have those treaties amended," Hylton said.
China is proposing there should be a worldwide ban on ketamine - the drug that can lead to users needing to have their bladders removed. But ketamine is used as an anaesthetic drug in much of Africa, and there are fears further international controls could affect medical usage too. The Chinese say that they are requesting the lowest level of restriction - known as schedule four - which would not affect its use for medical purposes. But Dr Kabwe in Lusaka's main hospital says any restriction will create a level of bureaucracy that will prohibit its use.
In a dispute that pits the war on drugs against global health needs — and one UN agency against another — a pair of Canadian researchers is spearheading a last-ditch bid to keep a widely used anesthetic from being declared an illicit narcotic.
Scheduling ketamine would restrict its availability worldwide, which would lead to harmful impact on animal health and welfare, as well on public health. The World Medical Association is urging its 111 member associations to lobby their governments to oppose scheduling the anaesthetic agent Ketamine as a controlled drug.
The Commission on Narcotic Drugs (CND) in Vienna will decide next week between two opposite proposals by China and the WHO about international control of ketamine, an essential anaesthetic in human and veterinary medicine. China originally proposed bringing ketamine under the 1971 Convention’s most severe control regime of Schedule I, which would dramatically affect its availability for surgery in poor rural settings and emergency situations. The WHO Expert Committee reviewed all the evidence and advised against any international control of ketamine, arguing it would trigger a public health disaster.
A proposal that is about to come before the UN to restrict global access to ketamine, a drug abused in rich countries, would deprive millions of women of lifesaving surgery in poor countries, according to medicines campaigners.
The UN Commission considers to bring ketamine under the control of the 1971 Convention on Psychotropic Substances contrary to WHO recommendations. The 58th Session of the UN Commission on Narcotic Drugs (CND) in March 2015 has been asked to consider a Chinese proposal to place ketamine – an essential medicine used for anaesthesia – in Schedule I of the 1971 Convention (E/CN.7/2015/7 and E/CN.7/2015/81). Ketamine is the only available anaesthetic for essential surgery in most rural areas of developing countries, home to more than 2 billion of the world’s people. Scheduling ketamine under any of the 1971 treaty schedules will reduce its availability and further deepen the already acute crisis of global surgery.
Ketamine is an essential medicine used for anaesthesia. It is the only available anaesthetic for essential surgery in most rural areas of developing countries, home to more than 2 billion of the world’s people. Scheduling ketamine will leave these populations with no alternative anaesthesia for essential surgery, and will further deepen the already acute crisis of global surgery.
The upcoming United Nations General Assembly Special Session on Drugs (UNGASS) in 2016 is an unprecedented opportunity to review and re-direct national drug control policies and the future of the global drug control regime. As diplomats sit down to rethink international and domestic drug policy, they would do well to recall the mandate of the United Nations, not least to ensure security, human rights and development.
The United States federal government is considering easing its position on marijuana, reclassifying it as a less dangerous drug in what marijuana advocates say reflects the changing attitudes nationwide. But drug specialists fear the watershed moment for marijuana research could be a slippery slope for addicts. The Food and Drug Administration (FDA) is reviewing marijuana’s classification to consider changing it from a Schedule I drug. (See also: FDA to evaluate marijuana for potential reclassification as less dangerous drug)
The US Food and Drug Administration is reviewing the medical evidence surrounding the safety and effectiveness of marijuana, a process that could lead to the agency downgrading the drug's current status as a Schedule I drug, the most dangerous classification. "FDA conducts for Health and Human Services a scientific and medical analysis of the drug under consideration," FDA Press Officer Jeff Ventura said. "HHS then recommends to DEA that the drug be placed in a given schedule. DEA considers HHS’ analysis, conducts its own assessment, and makes a final scheduling proposal in the form of a proposed rule." (See also: Scheduling in the international drug control system)
A new decree that overhauls Italy's drugs laws paves the way for releasing "thousands of convicted smalltime drug dealers from prison". The move follows parliamentary approval of a decree earlier this month that overhauls Italy's drugs laws and reclassifies marijuana as a soft rather than a hard narcotic. The new law also effectively removes jail time as a sentence for smalltime dealers, offering community service and other options in its place. (See also: Council of Europe lauds Italian moves on prison overcrowding)
Khat is as potent as a strong cup of coffee and has no organised crime involvement – yet the government wants to spend £150m on a ban that would create far more severe problems. When the Advisory Council on the Misuse of Drugs, the government's expert advisors, were asked to consider khat, they said that it would be "inappropriate and disproportionate" to ban it. The cross-party home affairs select committee, on which I serve, produced a unanimous report opposing a ban. And yet the home secretary plans to do it anyway.
On February 12, the Constitutional Court ruled that the Fini-Giovanardi law setting out penalties related to the sale and possession of illegal drugs, was improperly approved, and abrogated the law. Since then, Italy has returned to previous regulations that imposed lighter sanctions on cannabis users. Prisoners' rights organisations argued that harsh drug laws have created a booming prison population in a system that is already overcrowded. Since January 2013, Italy's prisons have been under the scrutiny of the European Court of Human Rights.
Reflections upon this year’s CND are mixed. On the one hand, some states went further than ever before in openly challenging the current regime on the grounds that, after a century, it needs modernising. That the government of Uruguay is currently considering a domestic policy on cannabis that would put it in breach of the Single Convention shows that, in one instance at least, we have moved beyond rhetoric and posturing.